Sweet indeed. So is the following: MS. Habba step down

New Post Public Reply Private Reply Replies (0) Message Board
Bhawks SaltyMutt #114965
151
Sweet indeed. So is the following:

MS. Habba step down here. Take out your mobile phone and turn it on. Text your mother that there is serious doubt about you becoming a lawyer. You come in here with a skull full of mush; and it appears you will leave with same.

Alina Habba

Now that the dust has settled, here's my take on Habba, Trump, and the Carroll trial.

https://www.democraticunderground.com/100218635595

Habba seemed oblivious to the basic courses in law school of evidence, trial advocacy, and even orientation where you're introduced to civil procedure.

According to Attorney Ethics, you are charged with "zealous representation" of your client. IOW, you do whatever you can to put the position(s) of your client before the factfinder, whether it's a jury or a judge. You do your research, you consult your client, you're organized when you appear in court, and your presentation is coherent and persuasive.

What you don't do is whatever your client tells you to do. Just the opposite: you advise your client of the limitations of his/her/their/its case. And there's always some limitations. Maybe you don't have necessary provable facts. Maybe statutes and caselaw are not promising. I've had to sternly tell clients that they don't have much of a case and we can only fall back on trial where hopefully, adversarial counsel will make mistakes that can be reversed on appeal.

From where I'm sitting, Habba promised Trump they'd win no matter what. She'd tell the judge where to get off. She'd make judicial history and give him justice simultaneously. She'd promise the judge that Trump wouldn't pontificate on the stand, then let him do exactly that while looking helplessly at the judge. TRUMP would win the case, not Habba.

IMO, their "strategy" was to get a mistrial. Or get jury nullification where they'd award E. Jean Carroll something insulting like $1.00. Or get just one juror to refuse to award any amount.

Remember, they could have made a settlement offer of any amount at any time to make this spectacle to go away. But they didn't. They could have asked for the amount to remain undisclosed. They didn't.

And how about THIS: Trump could have publicly apologized to E. Jean Carroll during the trial. I've done this with clients who were legally culpable. Had them write letters of apology, give ALL the money they took back to the Court to give to the victims, and apologize for their actions publicly in court. Did they want to do it? Of course not. But we didn't have a case and they wanted the whole thing to go away. Result: The Court accepted their guilty pleas, apologies, and money BUT didn't impose any fines or prison for larceny. We were granted mercy because of our accepting responsibility and showing humility. Trump *might* have had a reduction in the judgment by the jury.

Alina Habba reminds me of those unfortunate compatriots in law school, where they're called on by the professor about an assigned case, and they end up looking like abject fools in front of 100 students as well as the professor. (It happened to me once -- and once is enough for you to dedicate yourself to being prepared in the future.)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 2

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 4

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 2

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 2

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading

Top 5 Most Recently Viewed Articles

Sprott Focus Trust Reports Quarterly Distribution and Insights

Updated Category News Views 195

Sprott Focus Trust Announces Quarterly Share Distribution In an uplifting update for investors, Sprott Focus Trust, Inc. (Nasdaq: FUND) has just declared a quarterly distribution of $0.1274 per share on its Common Stock. This distribution offers shareholders a choice between receiving payment in additional shares or cash. Set for disbursement on September 29, 2025,...

Continue Reading
Personal Injury Lawsuits: What You Need to Know Before Filing

Updated Category Personal Finance Views 1165

If you have been injured due to someone else's negligence or careless actions, you may be considering filing a personal injury lawsuit. Consulting a personal injury claim lawyer can help you understand your rights and the complexities involved in pursuing compensation. Personal injury lawsuits can be an effective way to recover damages for medical bills, lost wages, pain...

Continue Reading
Honeywell and Qualcomm Join Forces to Advance AI in Energy Sector

Updated Category News Views 188

Collaborating to Enhance AI Solutions in Energy Honeywell (NASDAQ: HON) and Qualcomm (NASDAQ: QCOM) Technologies, Inc. are making headlines with their groundbreaking collaboration aimed at revolutionizing artificial intelligence (AI) solutions within the energy sector. This partnership is a significant step towards enhancing Honeywell's automation offerings by seamlessly...

Continue Reading
Celebrating Diversity: The Best Gift for Foodies This Season

Updated Category News Views 106

Celebrating the Best Gift for Foodies Packed with Purpose (PwP), a Certified Woman-Owned and B Corp gifting company, has made headlines with its Black-Owned Spotlight Gift Basket, recently awarded as the Best Gift for Foodies. Understanding the Award Recognition This prestigious recognition comes from the USA Today 10Best Readers' Choice Awards, where a dedicated panel of...

Continue Reading
Coloplast A/S Updates Organic Growth and EBIT Margin Guidance

Updated Category News Views 620

Coloplast A/S Adjusts Financial Guidance for FY 2024/25 Coloplast A/S has revised its financial expectations for FY 2024/25, particularly in terms of organic growth and EBIT margin before special items. The anticipated organic growth has been adjusted to approximately 7%, down from the previous expectation of 8-9%. Additionally, the EBIT margin is now projected to be in...

Continue Reading